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 Glucocorticoid Toxicity Index provides a global quantifiable assessment tool to assess 
glucocorticoid associated morbidity. 
 Cumulative doses of steroids in ANCA associated vasculitis leads to worse 
glucocorticoid related toxicity 
 Whilst glucocorticoids remain the mainstay of AAV treatment, the narrow 




Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis (AAV) is an autoimmune 
disease. Induction remission and maintenance treatment typically includes high dose, 
tapering glucocorticoids (GC) in addition to other immunosuppressive medication. The use 
of Glucocorticoid Toxicity Index (GTI), provides a global, quantifiable assessment tool in 
which clinicians can assess GC associated morbidity.  Recent trials in AAV have exposed the 
need for systemic assessment of GC burden. In this small cohort study, we look to address 
these issues and the justification of newer GC sparing agents such as C5a inhibitors. 
 
Methods 
A retrospective cohort study of 43 patients with biopsy AAV was constructed from a single 
centre between 2012 to 2016 and followed up for 48 months.  The GTI table made up of 
adverse features used to quantify patients GC toxicity. Electronic patient records were 
reviewed and scores calculated according to published methods. GTI scores were compared 
with cumulative steroid doses at separate intervals as well as incidences of adverse features 
in relation to the treatment timeline.  
 
Results 
The mean age was 65.9 (± 11.06) years and treatment regimens consisted of glucocorticoids 
alongside cyclophosphamide or rituximab. Our results showed statistical significance in the 
association of cumulative GC doses and GTI scores (p=0.008, 95% CI, 1.31 to 8.05). Adverse 
features relating to mood disturbance and GC induced psychosis occurred early, in contrast 
to adrenal insufficiency which typically presented later in the follow up. Infection related 
adverse events were consistent throughout. 
 
Conclusions  
We demonstrated that higher, cumulative doses of steroids in AAV lead to worse 
glucocorticoid related toxicity. Using the GTI creates potential to individualise and quantify 
the adverse effects patients experience as a result of GC treatment and permits more 
patient centred management. Whilst glucocorticoids remain the main adjunctive 
immunosuppression of AAV treatment, the narrow therapeutic window supports the need 




Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis (AAV) is a complex 
autoimmune inflammatory disorder. It is characterised by inflammation and necrosis of 
small and medium sized blood vessels leading to tissue destruction and organ dysfunction. 
Immunosuppression is the mainstay of treatment.  
 
The European Vasculitis Society (EUVAS) has conducted several  large randomised control 
trails addressing various aspects of AAV treatment (1). The role of the role of B-cell 
depletion, cytotoxic and antimetabolite therapy in remission induction and remission 
maintenance therapy is well supported (1,2).Induction and maintenance treatment typically 
involves adjuvant glucocorticoid (GC) treatment and as a result, many AAV patients receive 
long term, high cumulative doses of GC as management of their AVV and any relapsed 
disease.   
 
With the exception of the recent PEXIVAS (3)and ADVOCATE (4) trials, there is a lack of 
evidence substantiating the role of glucocorticoid dosing and duration, with significant 
evidence of treatment related harm (5). The detrimental consequence of increasing GC 
doses has long been cited and the effects were recognised back in the 1950’s when steroids 
were given for many systemic diseases (6–8). Many of the side effects seen in autoimmune 
conditions such as AAV are often related to the duration of GC therapy (5,9). Adverse 
features can include steroid induced diabetes, hypertension, osteoporosis, cataracts and 
adrenal insufficiency (6,7,9). 
 
 
In more recent years there has been a gradual trend towards minimising exposure to high 
dose corticosteroids including  pulsed methylprednisolone especially in high risk or frail 
patients(10,11). This is also seen in other areas of nephrology, for example where GC 
treatment was once the mainstay treatment in the prevention of rejection in solid organ 
transplant medicine. However, steroid free transplantation is becoming increasingly 
common in order to reduce GC related toxicity(12,13). These practise-based changes and 
recent studies have in part shaped the way we approach GC prescribing but it still remains a 
relatively evidence free area especially with regards to the use of methylprednisolone. 
 
More recently, the term glucotoxicity has been coined and this has brought about the 
introduction of the Glucotoxicity index (GTI) (6). The GTI is a  global assessment tool which 
clinicians can use to quantitively assess the toxic effects of GC therapy and its associated 
morbidity at time intervals (6).  Whilst the adverse effects of GC are well known there is a 
lack of substantial data quantifying adverse outcomes or incidence of steroid related side 
effects (14). In 2014 Robson et al (5) demonstrated significant adverse effects relating to the 
duration of GC use in AAV. GC treatment contributed to the vasculitis damage index and this 
was of particular significance given those with a high index had an associated increased 
mortality (5,15). They demonstrated worsening outcomes over long term follow up and 
recommended clinicians to reduce GC use(5). 
 
The measurement of glucocorticoid related toxicity varies significantly in published data 
(6,14)and is often confounded by the impact of other concurrently administered 
immunosuppression. This study aims to evaluate the GTI in AAV as a as a comprehensive 
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and quantitative tool of assessing the steroid associated treatment burden in current 
management strategies.   Recent trials in AAV have exposed the need for systemic 
assessment of GC burden. In this small cohort study, we look to address these issues and 
the justification of newer GC sparing agents such as C5a inhibitors. 
Materials and Methods 
Data collection 
A cohort study of 43 ANCA positive patients with biopsy proven pauci-immune 
glomerulonephritis was constructed from a single centre between 2012 and 2016. Each 
patient was followed up for a total of 48 months. Patients who did not have a biopsy or 
where the biopsy was non diagnostic or demonstrated significant dense deposit disease 
were excluded. In addition, those with positive anti- glomerular basement membrane 
antibodies, dual pathology and secondary vasculitis were also excluded. Data was collected 
retrospectively and GTI scores were collated from electronic patient records and telephone 
calls with some patients. Cumulative doses of GC were calculated alongside GTI scores at 
seven separate intervals; 1, 3, 6, 12, 24, 36 and 48 months. Pulsed methylprednisolone at 
induction and relapse were reviewed and doses were converted to oral prednisolone dose 
equivalents, with all subsequent cumulative doses presented as prednisolone (mg).  
 
The primary outcome measures include the GTI scores alongside the cumulative steroid 
doses. Secondary outcome measures include the incidences of each adverse event and the 
timeline in which each event occurred in relation to commencing GC therapy. 
 
GTI scoring system 
The GTI is a tool which clinicians can use to validate and quantify the toxic effects of GC 
therapy at time intervals. Patient information from our cohort was compared against the 
glucocorticoid toxicity index in which there is a composite and specific list (Table 1).  Each 
patient was given a score relating to features on the composite list and this exercise was 
repeated at 7 separate intervals. This allowed for the measurement of change in the GTI 
over the 48 months follow up period. 
 
The items listed relate to commonly recognised adverse events as a result of cumulative 
steroid exposure. Scores range from - 36 to 439 with Cumulative Worsening Score (CWS) 
relating to an increase in GC toxicity burden. The Aggregate Improvement Score (AIS) is a 
negative score, reflecting an improvement in toxicity (16). The full details of the GTI scoring 
system, categories and components are described  in the paper by Miloslavsky et al (6).  
 
Statistical Analysis 
Differences of quantitative parameters between groups were assessed using both t and rank 
sum tests. 95% confidence intervals (CIs) are reported and the threshold for statistical 
significance throughout was a P value of less than 0.05. Repeated measures of GTI and 
steroid doses were summarised by the area under the curve and modelled using linear 
regression with backward selection. All statistical analyses were conducted in STATA V.16. 
For continuous variables, means and standard deviations were calculated and median and 





Approval for this study was obtained by The Centre for Health Research and Innovation on 
behalf of Lancashire Teaching Hospitals NHS Foundation Trust (Ref: SE-317). The study was 
approved as service evaluation, therefore formal ethics committee review was not required.  
Results  
Study Population 
Forty-three patients were identified, 23 female and 20 males with a mean age of 65.9 (± 
11.06) years at the time of presentation. All patients were ANCA positive: 44.2% (n= 19) 
positive for proteinase 3 (PR3) ANCA antibodies and 55.8% (n= 24) positive for 
myeloperoxidase (MPO) auto-antibodies and had a renal biopsy at diagnosis demonstrating 
evidence of pauci-immune glomerulonephritis. Baseline patient characteristics with 
subgrouping according to ANCA serology is outlined in Table 2 with no meaningful 
difference in age or gender across the two groups. One patient was lost to follow up, five 
patients died and one patient received a renal transplant during the follow up period. 
 
All patients had AAV with renal involvement and 69.8% had more than one system 
involvement, with three patients having more than five systems involved. The mean 
estimated glomerular filtration rate (eGFR (ml/min/1.73m2)), at presentation was 
23.3ml/min (± 18.1ml/min) with eight patients requiring initial renal replacement therapy. 
Of these eight patients, six (75%) regained independent renal function later in the study. 
Eight patients experienced relapsing disease during the follow up period and 2 patients 
reported worsening ENT disease on weaning GC’s. 
 
Treatment 
Induction therapy consisted of either intravenous cyclophosphamide or rituximab alongside 
daily oral GC. Pulsed intravenous methylprednisolone and plasma exchange were 
administered according to physician discretion. The dosing regimen of cyclophosphamide 
was adjusted for age and renal function in line with recommendations made by the 
European Vasculitis Study Group (2). The median cumulative dose of cyclophosphamide 
given was 5.4g (IQR 2.4-2.9g).  Rituximab was administered at a dose of 1g every two weeks 
for two doses. The dose taper of oral GC followed the regimen outlined by the CYCLOPS trial 
with variation according to physician discretion. Within the overall patient cohort, two 
patients died during the induction period, one as result of vasculitis and the other from a 
cerebral vascular event. 
 
Initial doses of oral prednisolone ranged between 60mg to 20mg daily. Intravenous pulsed 
methylprednisolone was given to 37.2% (n=16) of which most (n=12) received a total dose 
of 1.5 gram over 3 days. Two-thirds (65.9%) of patients had a 50% reduction in oral GC dose 
by week four. Of those receiving intravenous pulsed methylprednisolone the mean eGFR 
was 21.6 ml/min/1.73m2 (8 - 22.3ml/min) at presentation and the majority (62.5%) had 
more than one system involvement.  
 
Twelve patients received adjuvant plasma exchange with an average of 5.3 sessions. Within 
this subgroup, ten received concomitant pulsed intravenous methylprednisolone as part of 
remission induction therapy. The cumulative dose of prednisolone at 12 months was higher 
amongst patients receiving plasma exchange therapy; 5203.6mg vs. 4667.3mg. Remission 
maintenance therapy in the surviving 41 patients consisted of rituximab (n=17), 
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azathioprine (n=26), mycophenolic acid (n=3), methotrexate (n=3) and cyclophosphamide 
(n=1). 95.1% of those on maintenance therapy received concurrent daily maintenance oral 
GC.   
Cumulative steroid doses were calculated at seven separate time intervals. At the end of the 
48 months follow up period, over half (54.1%) of patients were steroid free. Of those who 
completed steroid therapy, the median GC treatment period was 34.5 months (IQR 24.2 – 
41.8 months). Amongst the seventeen patients still receiving GC treatment at the end of the 
study period, one patient was receiving 10mg/day prednisolone as a part of a reducing 
course following recent relapse and the remaining nine patients were on 5mg/day or less of 




GTI scores and cumulative steroid doses were calculated at fixed intervals. Scores ranged 
from 0 to 123 over the 4 year follow up period. Of the 37 patients included at the end of the 
study, only 12 patients (27.9%) had a GTI score of 0. Figure 1 shows the cumulative GC dose 
and GTI scores of individual patients at the end of the study period. With the exception of 
one patient, this demonstrates that at 48 months patients with a GTI score of over 60 had 
received over 9000mg of glucocorticoids. Using linear regression with backward selection, 
there was a statistically significant association demonstrated between the cumulative GC 
dose and GTI score with a p value of 0.008 and 95% confidence interval for the regression 
coefficient was 1.31- 8.05. There was no association between the use of pulsed intravenous 
methylprednisolone and GTI score at the end of the study period (p=0.8). Similarly, there 
was no difference in cumulative GC dose and GTI scores in those that were treated with 
cyclophosphamide (p=0.72) or rituximab (p =0.36). 
 
Overall PR3 positive patients received higher cumulative doses of glucocorticoids than MPO 
positive patients at the end of the study period; 9330.5mg vs. 5665mg. In line with this a 
larger proportion of patients in the PR3 group had evidence of GC toxicity at follow up 
compared to those with MPO positivity, 73.7 vs. 65% respectively. There was no significant 
difference in relapse rates but higher mortality was associated with MPO positive disease 
(table 2).  
 
 
Incidence of toxicity 
The incidence of adverse features related to steroid therapy both from the composite and 
specific list increased over the follow up period. Three patients (7.0%) demonstrated GC 
toxicity as early as 4 weeks. At the end of the follow up period, 27 patients (71.9%) 
demonstrated GC toxic effects (Table 2).   
 
Infections, reduced bone density and increasing BMI were the commonest adverse effects 
of GC therapy. Nearly a quarter (23.2%) had an improvement in their GTI score (AIS) during 
the follow up period, with the majority seeing an improvement in weight, glucose tolerance 
and blood pressure. The AIS occurred after the first year of treatment and following a 




Figure 2 outlines the distribution of adverse events related to glucocorticoid toxicity along 
the follow up period. As expected, certain dose dependant adverse features such as mood 
disturbance and steroid induced psychosis occurred early on in the treatment course. This is 
in contrast to adrenal insufficiency that occurred later in the follow up period, with a 
median time of 21 days (IQR 18-24) and 1059 days (IQR 895-1224) respectively. 
 
Figure 3 shows the percentage distribution of specific GC related adverse effects. Weight 
gain, increased body mass index (BMI), steroid induced diabetes and gastrointestinal issues 
such peptic ulcer disease occurred mostly within the first year of treatment while reduced 
bone density and osteoporotic fractures occurred on average between two to three years 
into GC therapy.  
 
Infection related adverse events were largely consistent throughout the duration of follow 
up as demonstrated in Figure 2. This can be attributed to baseline immunosuppression 
rather than GC alone.   Five patients scored 19 on the composite list (table 1) for having oral 
candidiasis and or uncomplicated varicella zoster infections. Oral fluconazole treatment was 
prescribed to 90.2% (n=37) of patients and all patients that developed oral candidiasis 
received appropriate fluconazole prophylaxis. Six patients scored 93 points due to grade 3 
infection which was defined as needing hospitalisation and or intravenous antibiotics. These 
infections occurred within the first year of commencing treatment. Co-Trimoxazole 
prophylaxis was prescribed in 97.6%(n=40) of patients and there were no incidences of 
Pneumocystis jirovecii infection.  
 
Reduced bone density and fragility fractures were recognised in 24.4% and 7.3% of patients 
respectively. All three patients that suffered fragility fractures had evidence of reduced 
bone mineral density on Dual Energy X-ray Absorptiometry (DEXA) scan. Bone protection 
was prescribed in the form of bisphosphates, vitamin D replacement and calcium 
supplements. 80.5% (n=33) received calcium supplements and 36.5% (n=15) were treated 
with Bisphosphonates. Of those that didn’t receive bisphosphonate treatment the median 
eGFR was 26 ml/min/1.73m2 (IQR 13.5-46ml/min) which may have been a contributory 
factor.  
Discussion 
This retrospective study looks at the impact of prolonged exposure to glucocorticoids using 
a novel scoring system. Whilst the effects of GC toxicity are well recognised, there has not 
previously been a tool that enables clinicians to quantify the toxic effects of GC treatment at 
an individual level. There have been several studies demonstrating the correlation between 
steroid exposure and GC toxicity however with the exception of the recent ADVOCATE 
(4)trial, there have been no other studies that have evaluated GTI scores in the context of 
AAV. Our data demonstrated that higher cumulative doses of GC’s led to more adverse 
effects of therapy and a quantitative increase in GC toxicity using this tool. 
 
The concept of systematically measuring GC toxicity in the form of GTI is new and warrants 
further validation. A study in 2020 by McDowell et al (17) looked at a variation of the 
glucocorticoid toxicity index (GTI 2.0) in severe asthma. It demonstrated that GTI scores 
were not only associated with GC doses but also correlated with patient reported outcome 
measures (PROMS). Using tools such as the Mini-asthma quality of life questionnaire 
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(AQLQ), they demonstrated strong correlation with GTI scores and patients reported quality 
of life (17). 
 
At present steroids remain a cornerstone of AAV treatment, but more recently studies are 
looking at ways in which to reduce steroid exposure. McGovern et al (10) looked at lower 
dose GC in the management of ANCA associated vasculitis in elderly and frailty groups. The 
median cumulative dose of prednisolone at 3 months in this study was slightly lower than 
the cumulative doses seen in our cohort; 2030 mg (IQR 1785–2167), 2520mg (IQR 1995-
3495) respectively.  The outcomes reported by McGovern et al (10) supported a low-dose 
glucocorticoid regime in favour of higher daily doses or pulsed methylprednisolone at 
induction. This was further supported by retrospective, multi-centre study of 114 patients in 
which pulsed IV methylprednisolone was associated with increased risk of infection and 
steroid induced diabetes and offered no benefit in the treatment of AAV compared to high 
dose oral corticosteroids (18).  
 
In our present study, infection was the most common toxicity amongst our cohort with the 
incidence of infection occurring throughout the follow up period. Many patients 
experienced oral candidiasis and varicella zoster infections and some suffered more serious 
effects such as sepsis requiring hospitalisation.  It is important to note that all patients in 
our cohort received steroids concurrent to other immunosuppressive therapies and 
therefore the specific role of GC in infection related toxicity is not in isolation. Furthermore, 
other vasculitic contributing factors such as damaged sino-respiratory mucosa may have 
also had a role in the development of infections.  
 
Steroid induced mineral bone density disease was also noted in our cohort. Its incidence 
trended towards a delayed onset, correlating with a higher cumulative GC dose. One 
potential confounder is the demographic risk factors of our cohort (age > 60yrs and female 
gender).  Similar features have been recognised in other publications (1) and the role of 
prophylactic bone protection is vital. Whilst over half the patients in our cohort were steroid 
free at 48 months, many continued on low dose, maintenance steroids further exposing 
them to collective side effects. 
 
 
With larger trials such as PEXIVAS identifying non inferiority of lower dose GC treatment and 
potential reductions in the incidence of severe infection (3,11), it has made way for other 
trials to look at GC sparing treatments. Avacopan (CCX168) is a selective C5a receptor 
inhibitor which has been used as an adjuvant to reduce GC exposure significantly in the 
management of AAV. The recent landmark trial ADVOCATE(4) published earlier this year, 
has demonstrated that not only is avacopan effective in the management of AAV but 
reports significantly fewer adverse effects related to GC treatment compared to standard 
steroid treatment. It suggests that avacopan precludes the need for high dose glucocorticoid 
treatment in these patients (4,19,20). Furthermore, the trial used GC toxicity index as a 
secondary end point and demonstrated GTI cumulative worsening scores (GTI-CWS) that 
were  higher in prednisolone group compared to the avacopan group(4). Not only does this 
promote the use of GC sparing agents and highlight the adverse effects of GC treatment 
supported by the findings in our cohort, but it also highlights the use of GTI in clinic trials 





Within the world of nephrology, the use of steroids is not only limited to ANCA associated 
vasculitis. It is used as standard of care in the management of other conditions such as 
minimal change disease, membranous and IgA nephropathy. Whilst GC remain imperative 
to the treatment in many of these conditions, the narrow therapeutic index means that 
close observation and monitoring is essential.  
 
The findings of our study should be considered within the context of its limitations. Firstly, 
we recognise that the observational nature of the study in addition to other confounds such 
as immunosuppressive medication, plasma exchange and active vasculitis are all potentially 
contributory to the development of adverse effects. It is not possible to fully attribute all the 
adverse effects discussed to glucocorticoid treatment alone. However, panel of scientific 
experts who developed the GTI defined the features to be included in the composite GTI list 
based on different domains (6). These included the likelihood of adverse features occurring 
in over 5% in patients exposed to GCs, with toxicity being more likely a result of the GC 
therapy than the disease itself. Additionally any measurements and scores were not 
dependent on or requiring invasive procedures or imaging (6). Other adverse features that 
were considered significant but had the potential be confounded by other features such as 
underlying disease or other treatments were included in the specific list. Secondly, the 
retrospective nature of our study may also lend itself to inaccuracies in the reporting and 
documentation of some mild side effects such as mood disturbance or skin changes. This is 
likely to have led to an under representation of the adverse features. Thirdly, our relatively 
small sample size may restrict the accuracy of our results. 
 
Progressing the role of GTI in the assessment and management of renal patients treated 
with GC will be of significant value.  Calculating a baseline GTI score at induction with 
prospective monitoring, will help identify those patients at increased risk of developing toxic 
effects from prolonged steroid exposure. It is well known that there is a degree of genetic 
predisposition to GC toxicity (21). The role of pharmacogenetics alongside tools such as the 
GTI will allow for more patient centred management and tailored treatment plans (22). 
 
In spite of a relatively small cohort, this study has demonstrated the use of measuring GTI in 
AAV patients. We have shown that cumulative doses of steroids in AAV leads to worsening 
glucocorticoid related toxicity. Using the GTI tool allows us to individualise and quantify 
these adverse effects patients experience which in turn will improve patient centred 
management. We have also shown that the incidence of adverse features relating to GC 
exposure occur at different stages with a persistent risk of infection.  This data supports the 
need for further work evaluating GC-sparing treatments, the assessment of steroid toxicity 
and its relation to clinical outcomes as well as patient reported outcome measures. This 
pertinent need is not only restricted to AAV; whilst GC remains imperative in the treatment 
of a range of nephrological conditions, the narrow therapeutic index means that close 
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Table 1: The Glucocorticoid Toxicity Index is made up of a composite  and specific list 
relating to glucocorticoid toxicity (6). The composite list includes features of GC toxicity that 
are weighted and given numerical scores. The specific list includes adverse features of GC 
treatment but considered significant but are not given a numerical score. Scores can range 
from - 36 to 439 with increasing scores relating to an increase in GC toxicity burden and 
negative scores reflecting an improvement in toxicity (16). 
Composite GTI Item weight Specific List 
BMI 
Improvement in BMI –8 Major increase in BMI 
No change in BMI 0  
Moderate increase in BMI 21  
Major increase in BMI 36  
Glucose tolerance 
Improvement in glucose tolerance -8 Diabetic retinopathy 
No change in glucose tolerance 0 Diabetic nephropathy 
Worsening of glucose tolerance 32 Diabetic neuropathy 




Improvement in blood pressure −10 Hypertensive emergency  
No change in blood pressure 0 Posterior reversible encephalopathy 
syndrome 
Worsening hypertension 19  




Improvement in lipids  -9  
No change in lipids 0  
Worsening hyperlipidaemia 10  




Improvement in bone density  -1 Major decrease in bone density 
No change in bone density 0 Insufficiency fracture 
Decrease in bone density 29  
Steroid myopathy 
No steroid myopathy 0 Severe steroid myopathy 
Mild steroid myopathy 9  
Moderate steroid myopathy or greater  63  
Skin Toxicity 
No skin toxicity 0 Severe skin toxicity 
13 
 
Mild skin toxicity 8  
Moderate skin toxicity or greater 26  
Neuropsychiatric toxicity 
No neuropsychiatric symptoms 0 Psychosis 
Mild neuropsychiatric symptoms 11 GC-induced violence 
Moderate neuropsychiatric symptoms 
or greater 
74 Other severe neuropsychiatric 
symptoms 
Infection 
No significant infection 0 Grade IV infection 
Oral/vaginal candidiasis or 
uncomplicated zoster 
19 Grade V infection 
Grade III infection or greater 93  
Endocrine  Adrenal insufficiency 
Gastrointestinal 
  Perforation, Peptic ulcer disease 
Musculoskeletal 
  Avascular necrosis, Tendon rupture 
Ocular 
  Central serous retinopathy, 
intraocular pressure elevation, 
posterior subcapsular cataract. 







Table 2: Shows the different demographics between PR3 and MPO antibody positive 
vasculitis patients. The table shows the induction treatment, relapse and mortality results 
associated with each cohort. Cumulative steroid doses are demonstrated as median 
cumulative doses with IQR in milligrams (mg). In addition, the number of patients suffering 
for GC related toxicity at separate time intervals are also shown. Percentages of patients 
scoring for features of GC toxicity as per the composite list in the glucocorticoid Toxicity 
Index are presented. All percentages are calculated based on the number of patients alive at 








Age, years (SD) 65.9 (± 11.06) 58.8 (± 10.75) 71.6 (± 7.97) 
Sex (M:F) 20:23 9:10 11:13 
eGFR at diagnosis (Median, 
IQR), ml/min 
18 (10.5-27.5) 19 (9-28) 18 (12.5-26.3) 
Induction Treatment 
Plasma Exchange 12 8 4 
IV Methylprednisolone 16 7 9 
Cyclophosphamide 39 17 22 
Rituximab 4 2 2 
Cumulative steroid dose, mg (median, IQR) 






6 months 3870  
(2826.3 – 4412.5) 
4060 
(3432.5 – 4502.5) 
3360 
(2795-4200) 


















Number of patients scoring on the composite GTI list (%) 
1 month 3 (7.0) 1 (5.3) 2 (8.3) 
6 months 14 (35) 7 (36.8) 7 (32) 
1 year 20 (51.3) 11 (57.9) 9 (42.9) 
2 years 26 (66.7) 14 (73.7) 13 (61.9) 
4 years 27 (71.1) 14 (73.7) 13 (65) 
Relapsed disease (n) 8 5 3 
ESRF (n) 2 2 0 
Mortality (n) 5 0 5 
 
Proteinase 3 antibodies (PR3), Myeloperoxidase antibodies (MPO), Male (M), Female (F), 






Figure 1: Shows the cumulative GC dose and GTI scores of individual patients at the end of 
the study period. The graph shows that at the 4 year follow up, for those still included in the 
study, a patient with a GTI score of over 60 had received over 9000mg of glucocorticoids 





















Cummulative steroid dose (mg) 
16 
 
Figure 2: Shows the number of adverse events relating to each category of the 
glucocorticoid toxicity index over the 48 month follow up period. Each adverse event is 
scored once and the graph shows the distribution of onset for each adverse feature. 
The graph shows the number of infections was highest in the first few months and 
continued throughout the follow up period. Neuropsychiatric presentations occurred early 
in GC treatment in contrast to adrenal insufficiency which appeared to presented later, 
typically after 18months of GC treatment.  
 
 






Figure 3: Shows the percentage of adverse effects related to glucocorticoid treatment 
within our cohort of patients over the 4 year follow up period.  Changes in BMI were 
determined by increases in weight of over 5kg, raised blood pressure was assessed based on 
a rise of over 20mmHg from baseline or needing up titration of antihypertensive 
medications to keep BP in range. Infections included anything from oral thrush to sepsis as 
explained in the composite GTI list. 
 
Body mass index (BMI), Blood pressure (BP), Gastrointestinal (GI) side effects include 
gastritis and peptic ulcer disease.  
 
